Merck writes off big bet on CETP drug anacetrapib

Merck, the last big firm standing in the once-hyped CETP field, has opted against filing for approval of anacetrapib. The Big Pharma reached the decision after going over a mixed set of data from its…
Read the full story: FierceBiotech: Biotech